ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.89+0.08 (+2.10%)
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
ARS Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
ARS Pharmaceuticals's total assets was $251.48M at Sep 30, 2026. For fiscal 2025 it was $327.65M, down 6.7% from the year before. The highest annual figure on record is $394.80M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $327.65M | -6.7% |
| FY2024 | Dec 31, 2024 | $351.15M | +50.6% |
| FY2023 | Dec 31, 2023 | $233.19M | -17.1% |
| FY2022 | Dec 31, 2022 | $281.44M | +358.0% |
| FY2021 | Dec 31, 2021 | $61.45M | -84.4% |
| FY2020 | Dec 31, 2020 | $394.80M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $251.48M | -32.5% |
| Q2 FY2026 | Jun 30, 2026 | $249.50M | -20.4% |
| Q1 FY2026 | Mar 31, 2026 | $287.57M | -12.1% |
| Q4 FY2025 | Dec 31, 2025 | $327.65M | -6.7% |
| Q3 FY2025 | Sep 30, 2025 | $372.80M | +71.3% |
| Q2 FY2025 | Jun 30, 2025 | $313.47M | +41.2% |
| Q1 FY2025 | Mar 31, 2025 | $327.32M | +43.8% |
| Q4 FY2024 | Dec 31, 2024 | $351.15M | +50.6% |
| Q3 FY2024 | Sep 30, 2024 | $217.60M | -12.5% |
| Q2 FY2024 | Jun 30, 2024 | $221.97M | -14.2% |
| Q1 FY2024 | Mar 31, 2024 | $227.58M | -16.1% |
| Q4 FY2023 | Dec 31, 2023 | $233.19M | -17.1% |
| Q3 FY2023 | Sep 30, 2023 | $248.56M | -8.3% |
| Q2 FY2023 | Jun 30, 2023 | $258.75M | -12.0% |
| Q1 FY2023 | Mar 31, 2023 | $271.19M | -13.2% |
| Q4 FY2022 | Dec 31, 2022 | $281.44M | +358.0% |
| Q3 FY2022 | Sep 30, 2022 | $271.06M | -23.1% |
| Q2 FY2022 | Jun 30, 2022 | $294.00M | -19.9% |
| Q1 FY2022 | Mar 31, 2022 | $312.47M | -18.2% |
| Q4 FY2021 | Dec 31, 2021 | $61.45M | -84.4% |
| Q3 FY2021 | Sep 30, 2021 | $352.56M | – |
| Q2 FY2021 | Jun 30, 2021 | $366.98M | – |
| Q1 FY2021 | Mar 31, 2021 | $382.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $394.80M | – |
See a number that looks wrong?